<DOC>
	<DOC>NCT00567918</DOC>
	<brief_summary>To investigate the long-term efficacy and safety of FK506 ophthalmic suspension in patients with vernal keratoconjunctivitis</brief_summary>
	<brief_title>Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis</brief_title>
	<detailed_description>To give a chance of continuous use of 0.1% FK506 ophthalmic suspension to patients with vernal keratoconjunctivitis who were enrolled in the FJ-506D-AC09 study, long-term safety and efficacy were evaluated. Primary efficacy endpoint was the mean change from the baseline (before the treatment) in total score for objective clinical signs.</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Vernal keratoconjunctivitis patients who were enrolled in the FJ506DAC09 study Patients who wish to receive continuous administration of FK506 ophthalmic suspension Subjects who needed prohibited concomitant therapy at the initiation of the study Subjects who needed to wear contact lenses during treatment period on a testing eye Subjects with complicating an eye infection</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Keratoconjunctivitis</keyword>
	<keyword>Vernal keratoconjunctivitis</keyword>
	<keyword>FK506</keyword>
	<keyword>Tacrolimus</keyword>
</DOC>